Asher Biotherapeutics, Inc
- Biotech or pharma, therapeutic R&D
We aim to optimize the efficacy and safety of immunotherapies using cis-targeting to direct immunomodulators specifically to the desired immune cell type. Our lead program AB248, an IL-2 targeted to CD8 effector T cells, is in Phase 1 clinical trials.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}